Morgan Stanley
MBVX

Morgan Stanley’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Morgan Stanley’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-125
Closed – – 6783
2017
Q3 		$0 Buy
+125
New +$273 ﹤0.01% 6700

Other funds holding MBVX

Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BW
Bison Wealth Atlanta, Georgia $454M AUM 22.8% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
DRD
Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Morgan Stanley's MBVX Position: Q4 2017 in Review

Morgan Stanley sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q4 2017, closing a stake of 125 shares.

Morgan Stanley first reported a position in MBVX in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 15 funds tracked by Wall St. Rank hold MBVX as of Q4 2017.

  • Morgan Stanley reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q4 2017 after selling out during the quarter.
  • Morgan Stanley sold 125 MABVAX THERAPEUTICS HLDGS INC shares in Q4 2017.
  • Morgan Stanley first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2017 and held it in 1 quarter.
  • Morgan Stanley's MABVAX THERAPEUTICS HLDGS INC position peaked at $0 in Q3 2017.
  • 15 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q4 2017.

Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.